1.
O¨ntu¨rk ÖA, Bilge ŞY, Bilgin M, Kas¸ifogˆlu T. Are HLA B-27 negative and positive ankylosing spondylitis patients different? J Turkish Society Rheumatol. 2021;13(2):54-58. doi:10.4274/raed.galenos.2021.49469
2.
Gran J, Teisberg P, Olaissen B, Thorsby E, Husby G. HLA-B27 and allotypes of complement components in ankylosing spondylitis. J Rheumatol. 1984;11(3):324-326.
3.
Braun J, Bollow M, Remlinger G, et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum. 1998;41(1):58-67. doi:10.1002/1529-0131(199801)41:1<58::AID-ART8>3. 0.CO;2-G
4.
Gunal EK, Sarvan FO, Kamali S, et al. Low frequency of HLA-B27 in ankylosing spondylitis patients from Turkey. Joint Bone Spine. 2008; 75(3):299-302. doi:10.1016/j.jbspin.2007.06.021
5.
Garcia-Montoya L, Gul H, Emery P. Recent advances in ankylosing spondylitis: understanding the disease and management. F1000Res. 2018;7:F1000 Faculty Rev-1512. doi:10.12688/f1000research.14956.1
6.
Akkoc¸ N, Yarkan H, Kenar G, Khan MA. Ankylosing spondylitis: HLA-B* 27-positive versus HLA-B* 27-negative disease. Curr Rheumatol Rep. 2017;19(5):26. doi:10.1007/s11926-017-0654-8
7.
Caffrey MF, James DC. Human lymphocyte antigen association in ankylosing spondylitis. Nature. 1973;242(5393):121. doi:10.1038/ 242121a0
8.
Schlosstein L, Terasaki PI, Bluestone R, Pearson CM. High association of an HL-A antigen, W27, with ankylosing spondylitis. N Engl J Med. 1973;288(14):704-706. doi:10.1056/NEJM197304052881403
9.
Kim TJ, Na KS, Lee HJ, Lee B, Kim TH. HLA-B27 homozygosity has no influence on clinical manifestations and functional disability in ankylosing spondylitis. Clin Exp Rheumatol. 2009;27(4):574-579.
10.
Alamanos Y, Papadopoulos NG, Voulgari PV, Karakatsanis A, Siozos C, Drosos AA. Epidemiology of ankylosing spondylitis in Northwest Greece, 1983-2002. Rheumatology (Oxford). 2004;43(5):615-618. doi:10. 1093/rheumatology/keh133
11.
Feldtkeller E, Khan MA, van der Heijde D, van der Linden S, Braun J. Age at disease onset and diagnosis delay in HLA B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int. 2003;23(2):61-66. doi:10.1007/s00296-002-0237-4
12.
Yang M, Xu M, Pan X et al. Epidemiological comparison of clinical manifestations according to HLA-B27 carrier status of Chinese ankylosing spondylitis patients. Tissue Antigens. 2013;82(5):338-343. doi:10.1111/tan.12186
13.
Chung HY, Machado P, van der Heijde D, D’Agostino MA, Dougados M. HLA-B27 positive patients differ from HLA-B27 negative patients in clinical presentation and imaging: results from the DESIR cohort of patients with recent onset axial spondyloarthritis. Ann Rheum Dis. 2011;70(11):1930-1936. doi:10.1136/ard.2011.152975
14.
Sampaio-Barros PD, Bertolo MB, Kraemer MH, Neto JF, Samara AM. Primary ankylosing spondylitis: patterns of disease in a Brazilian pop- ulation of 147 patients. J Rheumatol. 2001;28(3):560-565.
15.
Kim TJ, Kim TH. Clinical spectrum of ankylosing spondylitis in Korea. Joint Bone Spine. 2010;77(3):235-240. doi:10.1016/j.jbspin. 2009.11.015
16.
Khan MA, Kushner I, Braun WE. Comparison of clinical features in HLA-B27 positive and negative patients with ankylosing spondylitis. Arthritis Rheum. 1977;20(4):909-912.
17.
Jaakkola E, Herzberg I, Laiho K et al. Finnish HLA studies confirm the increased risk conferred by HLA-B27 homozygosity in ankylosing spondylitis. Ann Rheum Dis. 2006;65(6):775-780. doi:10.1136/ard.2005. 041103
18.
Amor B, Santos RS, Nahal R, Listrat V, Dougados M. Predictive factors for the longterm outcome of spondyloarthropathies. J Rheumatol. 1994; 21(10):1883-1887.
19.
Jung J, Bang CH, Seok H, Choi SJ, Song GG. Clinical findings of ankylosing spondylitis with and without human leukocyte antigen (HLA)-B27 and HLA-B51. Ann Acad Med Singap. 2019;48(10):321-329.
20.
Abdulhadi MM, Al-Musawi BM, Al-Osami MH. Molecular and serologic detection of HLA-B27 among ankylosing spondylitis patients with some clinical correlations. Iraqı Postgred Med J. 2018;17(3):261-270.
21.
Chang JH, McCluskey PJ, Wakefield D. Acute anterior uveitis and HLA-B27. Surv Opthalmol. 2005;50(4):364-388. doi:10.1016/j.survophthal.2005.04.003
22.
Wakefield D, Chang JH, Amjadi S, et al. What is new HLA-B27 acute anterior uveitis? Ocul Immunol Inflamm. 2011;19(2):139-144. doi:10.3109/09273948.2010.542269
23.
Machado P, Landewe R, Braun J, et al. Ankylosing spondylitis patients with and without psoriasis do not differ in disease phenotype. Ann Rheum Dis. 2013;72(6):1104-1107. doi:10.1136/annrheumdis-2012-202922
24.
Palm O, Moum B, Ongre A, Gran JT. Prevalence of ankylosing spondylitis and other spondyloarthropathies among patients with inflammatory bowel disease: a population study (the IBSEN study). J Rheumatol. 2002;29(3):511-515.
25.
Boonen A, vander Cruyssen B, de Vlam K, et al. Spinal radiographic changes in ankylosing spondylitis: association with clinical characteristics and functional outcome. J Rheumatol. 2009;36(6):1249-1255. doi:10.3899/jrheum.080831
26.
Ward MM, Hendrey MR, Malley JD, et al. Clinical and immunogenetic prognostic factors for radiographic severity in ankylosing spondylitis. Arthritis Rheum. 2009;61(7):859-866. doi:10.1002/art.24585
27.
Zhang S, Wang Y, Peng L, et al. Comparison of clinical features in HLA-B27 positive and negative patients with axial spondyloarthritis: results from a cohort of 4.131 patients. Front Med (Lausanne). 2020;23(7): 609562. doi:10.3389/fmed.2020.609562
28.
van Lunteren M, Sepriano A, Landewe´ R, et al. Do ethnicity, degree of family relationship, and the spondyloarthritis subtype in affected relatives influence the association between a positive family history for spondyloarthritis and HLA-B27 carriership? Results from the worldwide ASAS cohort. Arthritis Res Ther. 2018;20(1):166. doi:10.1186/s13075-018-1672-2
29.
Jaakkola E, Herzberg I, Laiho K, et al. Finnish HLA studies confirm the increased risk conferred by HLA-B27 homozygosity in ankylosing spondylitis. Ann Rheum Dis. 2006;65(6):775-780. doi:10.1136/ard.2005. 041103
30.
Omar D, Qian M, Almansoub HA, Dong L. The role of HLA B27 in the treatment response, functional limitation and disease activity in ankylosing spondylitis patients. Euro J Biomed Pharma Sci. 2019;6:537-544.